BACKGROUND: Observational studies have reported an association between male circumcision and reduced risk of HIV infection in female partners. We assessed whether circumcision in HIV-infected men would reduce transmission of the virus to female sexual partners. METHODS: 922 uncircumcised, HIV-infected, asymptomatic men aged 15-49 years with CD4-cell counts 350 cells per microL or more were enrolled in this unblinded, randomised controlled trial in Rakai District, Uganda. Men were randomly assigned by computer-generated randomisation sequence to receive immediate circumcision (intervention; n=474) or circumcision delayed for 24 months (control; n=448). HIV-uninfected female partners of the randomised men were concurrently enrolled (intervention, n=93; control, n=70) and followed up at 6, 12, and 24 months, to assess HIV acquisition by male treatment assignment (primary outcome). A modified intention-to-treat (ITT) analysis, which included all concurrently enrolled couples in which the female partner had at least one follow-up visit over 24 months, assessed female HIV acquisition by use of survival analysis and Cox proportional hazards modelling. This trial is registered with ClinicalTrials.gov, number NCT00124878. FINDINGS: The trial was stopped early because of futility. 92 couples in the intervention group and 67 couples in the control group were included in the modified ITT analysis. 17 (18%) women in the intervention group and eight (12%) women in the control group acquired HIV during follow-up (p=0.36). Cumulative probabilities of female HIV infection at 24 months were 21.7% (95% CI 12.7-33.4) in the intervention group and 13.4% (6.7-25.8) in the control group (adjusted hazard ratio 1.49, 95% CI 0.62-3.57; p=0.368). INTERPRETATION: Circumcision of HIV-infected men did not reduce HIV transmission to female partners over 24 months; longer-term effects could not be assessed. Condom use after male circumcision is essential for HIV prevention. FUNDING: Bill & Melinda Gates Foundation with additional laboratory and training support from the National Institutes of Health and the Fogarty International Center.
RCT Entities:
BACKGROUND: Observational studies have reported an association between male circumcision and reduced risk of HIV infection in female partners. We assessed whether circumcision in HIV-infectedmen would reduce transmission of the virus to female sexual partners. METHODS: 922 uncircumcised, HIV-infected, asymptomatic men aged 15-49 years with CD4-cell counts 350 cells per microL or more were enrolled in this unblinded, randomised controlled trial in Rakai District, Uganda. Men were randomly assigned by computer-generated randomisation sequence to receive immediate circumcision (intervention; n=474) or circumcision delayed for 24 months (control; n=448). HIV-uninfected female partners of the randomised men were concurrently enrolled (intervention, n=93; control, n=70) and followed up at 6, 12, and 24 months, to assess HIV acquisition by male treatment assignment (primary outcome). A modified intention-to-treat (ITT) analysis, which included all concurrently enrolled couples in which the female partner had at least one follow-up visit over 24 months, assessed female HIV acquisition by use of survival analysis and Cox proportional hazards modelling. This trial is registered with ClinicalTrials.gov, number NCT00124878. FINDINGS: The trial was stopped early because of futility. 92 couples in the intervention group and 67 couples in the control group were included in the modified ITT analysis. 17 (18%) women in the intervention group and eight (12%) women in the control group acquired HIV during follow-up (p=0.36). Cumulative probabilities of female HIV infection at 24 months were 21.7% (95% CI 12.7-33.4) in the intervention group and 13.4% (6.7-25.8) in the control group (adjusted hazard ratio 1.49, 95% CI 0.62-3.57; p=0.368). INTERPRETATION: Circumcision of HIV-infectedmen did not reduce HIV transmission to female partners over 24 months; longer-term effects could not be assessed. Condom use after male circumcision is essential for HIV prevention. FUNDING: Bill & Melinda Gates Foundation with additional laboratory and training support from the National Institutes of Health and the Fogarty International Center.
Authors: C Yang; B Dash; S L Hanna; H S Frances; N Nzilambi; R C Colebunders; M St Louis; T C Quinn; T M Folks; R B Lal Journal: AIDS Res Hum Retroviruses Date: 2001-03-01 Impact factor: 2.205
Authors: T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray Journal: N Engl J Med Date: 2000-03-30 Impact factor: 91.245
Authors: Ronald H Gray; Godfrey Kigozi; David Serwadda; Frederick Makumbi; Stephen Watya; Fred Nalugoda; Noah Kiwanuka; Lawrence H Moulton; Mohammad A Chaudhary; Michael Z Chen; Nelson K Sewankambo; Fred Wabwire-Mangen; Melanie C Bacon; Carolyn F M Williams; Pius Opendi; Steven J Reynolds; Oliver Laeyendecker; Thomas C Quinn; Maria J Wawer Journal: Lancet Date: 2007-02-24 Impact factor: 79.321
Authors: Robert C Bailey; Stephen Moses; Corette B Parker; Kawango Agot; Ian Maclean; John N Krieger; Carolyn F M Williams; Richard T Campbell; Jeckoniah O Ndinya-Achola Journal: Lancet Date: 2007-02-24 Impact factor: 79.321
Authors: R H Gray; N Kiwanuka; T C Quinn; N K Sewankambo; D Serwadda; F W Mangen; T Lutalo; F Nalugoda; R Kelly; M Meehan; M Z Chen; C Li; M J Wawer Journal: AIDS Date: 2000-10-20 Impact factor: 4.177
Authors: Ronald H Gray; Godfrey Kigozi; David Serwadda; Frederick Makumbi; Fred Nalugoda; Stephen Watya; Laurence Moulton; Michael Z Chen; Nelson K Sewankambo; Noah Kiwanuka; Victor Sempijja; Tom Lutalo; Joseph Kagayii; Fred Wabwire-Mangen; Renée Ridzon; Melanie Bacon; Maria J Wawer Journal: Am J Obstet Gynecol Date: 2008-10-30 Impact factor: 8.661
Authors: Richard G White; Judith R Glynn; Kate K Orroth; Esther E Freeman; Roel Bakker; Helen A Weiss; Lilani Kumaranayake; J Dik F Habbema; Anne Buvé; Richard J Hayes Journal: AIDS Date: 2008-09-12 Impact factor: 4.177
Authors: Godfrey Kigozi; Ronald H Gray; Maria J Wawer; David Serwadda; Frederick Makumbi; Stephen Watya; Fred Nalugoda; Noah Kiwanuka; Lawrence H Moulton; Michael Z Chen; Nelson K Sewankambo; Fred Wabwire-Mangen; Melanie C Bacon; Renee Ridzon; Pius Opendi; Victor Sempijja; Absolom Settuba; Denis Buwembo; Valerian Kiggundu; Margaret Anyokorit; James Nkale; Nehemia Kighoma; Blake Charvat Journal: PLoS Med Date: 2008-06-03 Impact factor: 11.069
Authors: Jairam R Lingappa; Erin Kahle; Nelly Mugo; Andrew Mujugira; Amalia Magaret; Jared Baeten; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; James Kiarie; Carey Farquhar; Grace John Stewart; Joseph Makhema; M Essex; Edwin Were; Kenneth Fife; Guy Debruyn; Glenda Gray; James McIntyre; Rachel Manongi; Saidi Kapiga; David Coetzee; Susan Allen; Mubiana Inambao; Kayitesi Kayitenkore; Etienne Karita; William Kanweka; Sinead Delany; Helen Rees; Bellington Vwalika; Robert W Coombs; Rhoda Morrow; William Whittington; Lawrence Corey; Anna Wald; Connie Celum Journal: PLoS One Date: 2009-04-30 Impact factor: 3.240
Authors: Timothy B Hallett; Kanwarjit Singh; Jennifer A Smith; Richard G White; Laith J Abu-Raddad; Geoff P Garnett Journal: PLoS One Date: 2008-05-21 Impact factor: 3.240
Authors: Amina A Chaudhry; Gail Berkenblit; Allen L Gifford; Joseph Cofrancesco; James Sosman; Lynn E Sullivan Journal: J Gen Intern Med Date: 2010-12-08 Impact factor: 5.128
Authors: Godfrey Kigozi; Maria Wawer; Absalom Ssettuba; Joseph Kagaayi; Fred Nalugoda; Stephen Watya; Fred Wabwire Mangen; Noah Kiwanuka; Melanie C Bacon; Tom Lutalo; David Serwadda; Ronald H Gray Journal: AIDS Date: 2009-10-23 Impact factor: 4.177